A Study of (LY3527727) Pirtobrutinib in Participants With Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma or Non-Hodgkin Lymphoma

Recruiting now · Phase 4

Conditions studied: Chronic Lymphocytic Leukemia, Non-Hodgkin Lymphoma

In brief

Study J2N-MC-JZ01 (JZ01) is an individual-study appendix (ISA) under master protocol J2N-MC-JZNY, and represents participants from the completed originator study, clinical study LOXO-BTK-18001/J2N-OX-JZNA. Participants in the originator study will have the opportunity to continue their assigned study intervention or continue their follow-up visits by transitioning to this study. This study will evaluate the long-term safety and efficacy of pirtobrutinib.

Key facts

Study ID

NCT06876662

Run by

Eli Lilly and Company

People needed

279

Starts

2025-05-20

Expected to finish

2032-12-01

Last updated by the study team

2026-03-02

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Are currently enrolled and active in the originator study, LOXO-BTK-18001. A participant is considered active in the study if they are:
• receiving study intervention
• in the short-term follow-up period, or
• in the long-term follow-up period

You may not qualify if…

• Were a participant in the Phase 1b cohort of Study LOXO-BTK-18001

Where it is running

• Derriford Hospital — Plymouth, United Kingdom (enrolling)
• Florida Cancer Specialists — Sarasota, Florida, United States (enrolling)
• The Emory Clinic — Atlanta, Georgia, United States (enrolling)
• Northwestern University — Chicago, Illinois, United States (enrolling)
• Dana-Farber Cancer Institute — Boston, Massachusetts, United States (enrolling)
• Mayo Clinic- Minnesota — Rochester, Minnesota, United States (enrolling)
• University Of Nebraska Medical Center — Omaha, Nebraska, United States (enrolling)
• Swedish Cancer Institute — Seattle, Washington, United States (enrolling)
• Medical College of Wisconsin — Milwaukee, Wisconsin, United States (enrolling)
• Flinders Medical Centre — Adelaide, Australia (enrolling)
• CHU de Nantes - Hotel Dieu — Nantes, France (enrolling)
• Ospedale San Raffaele — Milan, Italy (enrolling)
• Pratia MCM Krakow — Krakow, Poland (enrolling)
• Instytut Hermatologii I Transfuzjologii — Warsaw, Poland (enrolling)
• Seoul National University Hospital — Seoul, South Korea (enrolling)
• St James's University Hospital — Leeds, United Kingdom (enrolling)
• Churchill Hospital — Oxford, United Kingdom (enrolling)
• Sylvester Comprehensive Cancer Center — Miami, Florida, United States (enrolling)
• Northwell Health — Lake Success, New York, United States (enrolling)
• Memorial Sloan-Kettering Cancer Center (MSKCC) - New York — New York, New York, United States (enrolling)
• Duke University Medical Center — Durham, North Carolina, United States (enrolling)
• Ohio State University Comprehensive Cancer Center — Columbus, Ohio, United States (enrolling)
• University of Pennsylvania Hospital — Philadelphia, Pennsylvania, United States (enrolling)
• Tennessee Oncology — Nashville, Tennessee, United States (enrolling)
• University of Texas MD Anderson Cancer Center — Houston, Texas, United States (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.